A mini-review for cancer immunotherapy: Molecular understanding of PD-1/ PD-L1 pathway & translational blockade of immune checkpoints

Yongshu Li, Fangfei LI, Feng Jiang, Xiaoqing Lv, Rongjiang Zhang, Aiping LYU*, Ge ZHANG

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

93 Citations (Scopus)
1 Downloads (Pure)

Abstract

Interference of the binding of programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) has become a new inspiring immunotherapy for resisting cancers. To date, the FDA has approved two PD-1 monoclonal antibody drugs against cancer as well as a monoclonal antibody for PD-L1. More PD-1 and PD-L1 monoclonal antibody drugs are on their way in clinical trials. In this review, we focused on the mechanism of the PD-1/PD-L1 signaling pathway and the monoclonal antibodies (mAbs) against PD-1 and PD-L1, which were approved by the FDA or are still in clinical trials. And also presented is the prospect of the PD-1/PD-L1 immune checkpoint blockade in the next generation of immunotherapy.

Original languageEnglish
Article number1151
JournalInternational Journal of Molecular Sciences
Volume17
Issue number7
DOIs
Publication statusPublished - 18 Jul 2016

Scopus Subject Areas

  • Catalysis
  • Molecular Biology
  • Spectroscopy
  • Computer Science Applications
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry

User-Defined Keywords

  • Immunotherapy
  • Monoclonal antibodies (mAbs)
  • PD-1 (Programmed cell death protein 1)
  • PD-L1 (Programmed death-ligand 1)

Fingerprint

Dive into the research topics of 'A mini-review for cancer immunotherapy: Molecular understanding of PD-1/ PD-L1 pathway & translational blockade of immune checkpoints'. Together they form a unique fingerprint.

Cite this